Literature DB >> 3283174

Use of lectin histochemistry in pancreatic cancer.

C K Ching1, R Black, T Helliwell, A Savage, H Barr, J M Rhodes.   

Abstract

Lectin peroxidase histochemical analysis was carried out on pancreatic tissue from patients with pancreatic carcinoma and chronic pancreatitis and from subjects with normal pancreas to find a tumour specific pattern of lectin binding that would aid histological and cytological diagnosis. There were striking differences between the lectin binding characteristics of the different cell types in the normal pancreas. Acinar cells were uniformly positive for binding with wheat germ agglutinin and soy bean agglutinin while islet cells were usually negative for these lectins. Ulex europaeus I lectin however, was found not to be specific for endothelium, showing positivity also for acinar and ductal tissue. Griffonia simplicifolia II lectin was found to be highly specific for ductal epithelium, and because of this was tested in a hamster pancreatic cancer model where it was not specific for ductal epithelium, reflecting differing carbohydrate expression in the hamster pancreas. Pancreatic carcinomas and chronic pancreatitis bound all five lectins without any qualitative distinction from each other or from normal pancreatic tissue, but there was increased intensity of peanut agglutinin binding to secreted mucins in pancreatic carcinoma, which may be of potential use in radiolabelled lectin scanning.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3283174      PMCID: PMC1141433          DOI: 10.1136/jcp.41.3.324

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  20 in total

1.  Cancer of the pancreas (nonendocrine): a suggested morphologic classification.

Authors:  A L Cubilla; P J Fitzgerald
Journal:  Semin Oncol       Date:  1979-09       Impact factor: 4.929

2.  Ulex europaeus I lectin as a marker for tumors derived from endothelial cells.

Authors:  M Miettinen; H Holthofer; V P Lehto; A Miettinen; I Virtanen
Journal:  Am J Clin Pathol       Date:  1983-01       Impact factor: 2.493

3.  Alterations in human colonic mucin occurring with cellular differentiation and malignant transformation.

Authors:  C R Boland; C K Montgomery; Y S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

4.  Carcinoma-associated cytostructural antigenic alterations: detection by lectin binding.

Authors:  D R Howard; P Ferguson; J G Batsakis
Journal:  Cancer       Date:  1981-06-15       Impact factor: 6.860

5.  Early lesions during pancreatic carcinogenesis induced in Syrian hamster by DHPN or DOPN. I. Histologic, histochemical and radioautographic findings.

Authors:  M A Moore; M Takahashi; N Ito; P Bannasch
Journal:  Carcinogenesis       Date:  1983       Impact factor: 4.944

6.  Radioiodinated peanut lectin: clinical use as a tumour-imaging agent and potential use in assessing renal-tubular function.

Authors:  E A Abdi; V J Kamitomo; T A McPherson; Z Catz; G Boniface; B M Longenecker; A A Noujaim
Journal:  Eur J Nucl Med       Date:  1986

7.  Early lesions during pancreatic carcinogenesis induced in the Syrian hamster by DHPN or DOPN. II. Ultrastructural findings.

Authors:  M A Moore; M Takahashi; N Ito; P Bannasch
Journal:  Carcinogenesis       Date:  1983       Impact factor: 4.944

8.  Cells of origin of pancreatic cancer: experimental animal tumors related to human pancreas.

Authors:  D E Bockman
Journal:  Cancer       Date:  1981-03-15       Impact factor: 6.860

9.  A potent pancreatic carcinogen in Syrian hamsters: N-nitrosobis(2-oxopropyl)amine.

Authors:  P Pour; J Althoff; F W Krüger; U Mohr
Journal:  J Natl Cancer Inst       Date:  1977-05       Impact factor: 13.506

10.  Ultrastructural analysis of pancreatic carcinogenesis. VI. Early changes in hamster acinar cells induced by N-nitroso-bis(2-hydroxypropyl)amine.

Authors:  B Flaks; M A Moore; A Flaks
Journal:  Carcinogenesis       Date:  1982       Impact factor: 4.944

View more
  8 in total

Review 1.  The detection and discovery of glycan motifs in biological samples using lectins and antibodies: new methods and opportunities.

Authors:  Huiyuan Tang; Peter Hsueh; Doron Kletter; Marshall Bern; Brian Haab
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Characterizing Protein Glycosylation through On-Chip Glycan Modification and Probing.

Authors:  Bryan S Reatini; Elliot Ensink; Brian Liau; Jessica Y Sinha; Thomas W Powers; Katie Partyka; Marshall Bern; Randall E Brand; Pauline M Rudd; Doron Kletter; Richard Drake; Brian B Haab
Journal:  Anal Chem       Date:  2016-11-15       Impact factor: 6.986

3.  Analysis and prediction of cancerlectins using evolutionary and domain information.

Authors:  Ravi Kumar; Bharat Panwar; Jagat S Chauhan; Gajendra Ps Raghava
Journal:  BMC Res Notes       Date:  2011-07-20

4.  Newly established human pancreatic carcinoma cell lines and their lectin binding properties.

Authors:  N Nishimura; S Saito; Y Kubota; N Moto-o; K Taguchi; K Yamazaki; A Watanabe; H Sasaki
Journal:  Int J Pancreatol       Date:  1993-02

5.  Defining the Specificity of Carbohydrate-Protein Interactions by Quantifying Functional Group Contributions.

Authors:  Amika Sood; Oksana O Gerlits; Ye Ji; Nicolai V Bovin; Leighton Coates; Robert J Woods
Journal:  J Chem Inf Model       Date:  2018-08-22       Impact factor: 4.956

6.  Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer.

Authors:  C K Ching; J M Rhodes
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

7.  Identification of the peanut-agglutinin binding pancreatic cancer serum marker in pancreatic tissue extracts.

Authors:  C K Ching; J M Rhodes
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

8.  Wheatgerm agglutinin-mediated toxicity in pancreatic cancer cells.

Authors:  R E Schwarz; D C Wojciechowicz; A I Picon; M A Schwarz; P B Paty
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.